Efficacy and cardiovascular safety of daclizumab, mycophenolate mofetil, tacrolimus, and early steroid withdrawal in renal transplant recipients: a multicenter, prospective, pilot trial
- 1 August 2005
- journal article
- research article
- Published by Wiley in Clinical Transplantation
- Vol. 19 (4) , 475-482
- https://doi.org/10.1111/j.1399-0012.2005.00369.x
Abstract
SCOPUS: ar.jFLWINinfo:eu-repo/semantics/publisheKeywords
This publication has 34 references indexed in Scilit:
- Steroid-Withdrawal at 3 Days After Renal Transplantation with Anti-IL-2 Receptor α Therapy: A Prospective, Randomized, Multicenter StudyAmerican Journal of Transplantation, 2004
- New Onset Diabetes Mellitus in Patients Receiving Calcineurin Inhibitors: A Systematic Review and Meta-AnalysisAmerican Journal of Transplantation, 2004
- Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months1Transplantation, 2003
- Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation12Transplantation, 2003
- Ischemic heart disease after renal transplantationKidney International, 2002
- DOUBLE-BLIND COMPARISON OF TWO CORTICOSTEROID REGIMENS PLUS MYCOPHENOLATE MOFETIL AND CYCLOSPORINE FOR PREVENTION OF ACUTE RENAL ALLOGRAFT REJECTION1Transplantation, 2000
- The Banff 97 working classification of renal allograft pathologyKidney International, 1999
- A COMPARISON OF TACROLIMUS (FK506) AND CYCLOSPORINE FOR IMMUNOSUPPRESSION AFTER CADAVERIC RENAL TRANSPLANTATION1Transplantation, 1997
- MYCOPHENOLATE MOFETIL IN RENAL ALLOGRAFT RECIPIENTSTransplantation, 1997
- CyclosporineNew England Journal of Medicine, 1989